November 1, 2006
Lou Gehrig Memorial Award given to CytRx CEO
By Jeff Lavery
CytRx CEO Steven Kriegsman was awarded the Lou Gehrig Memorial Award in Los Angeles in recognition of CytRx's efforts to find a cure for amyotrophic lateral sclerosis (ALS).
ALS, or Lou Gehrig's disease, affects more than 120,000 people worldwide. In September, CytRx announced that its drug candidate arimoclomol was shown to be safe and tolerable at all three doses tested in its Phase IIa clinical trials in patients suffering from the ailment.
Subject to U.S. Food and Drug Administration approval, CytRx plans to proceed with initiating a Phase IIb clinical trial with arimoclomol for the treatment of ALS in Q3 of 2007.
CytRx Corp.'s Drug Discovery division is headquartered in Worcester.
WBJ Web Partners
Most Recent
Most Recent
0 Comments